KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Equity Average (2016 - 2025)

Inovio Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $10.4 million for Q3 2025.

  • For Q3 2025, Equity Average fell 87.78% year-over-year to $10.4 million; the TTM value through Sep 2025 reached $10.4 million, down 87.78%, while the annual FY2024 figure was $92.9 million, 45.29% down from the prior year.
  • Equity Average for Q3 2025 was $10.4 million at Inovio Pharmaceuticals, down from $39.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $545.1 million in Q2 2021 and bottomed at $10.4 million in Q3 2025.
  • The 5-year median for Equity Average is $184.3 million (2023), against an average of $228.9 million.
  • The largest annual shift saw Equity Average surged 439.56% in 2021 before it crashed 87.78% in 2025.
  • A 5-year view of Equity Average shows it stood at $426.6 million in 2021, then plummeted by 42.68% to $244.5 million in 2022, then tumbled by 47.76% to $127.8 million in 2023, then plummeted by 44.41% to $71.0 million in 2024, then tumbled by 85.35% to $10.4 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Equity Average are $10.4 million (Q3 2025), $39.9 million (Q2 2025), and $59.9 million (Q1 2025).